Supreme Court Declines CareDx Appeal in Natera Ad Dispute
The U.S. Supreme Court rejected CareDx's appeal in its false-advertising case against Natera, leaving a lower court ruling in place.
The U.S. Supreme Court refused Monday to hear an appeal from CareDx in its ongoing false-advertising legal battle with genetic testing rival Natera, Inc., effectively allowing a lower court's decision to stand and closing a significant avenue of relief for the diagnostics company.
The dispute centers on competing claims in the transplant-monitoring diagnostics space, where both CareDx and Natera market cell-free DNA tests used to detect organ rejection in transplant patients. False-advertising litigation of this kind can carry serious commercial consequences, as court findings may force companies to alter marketing materials and potentially affect their competitive positioning with hospitals and health systems.
Read more Record Debt Issuance of $570B Projected for 2026 Strains Markets →
By declining to take up the case, the nation's highest court left intact whatever ruling the appellate court had previously issued against CareDx, a outcome that could influence how the two companies compete for contracts and clinical adoption going forward. Supreme Court rejections of certiorari are not rulings on the merits, but they do signal that justices found no compelling federal question warranting review.
The decision lands at a sensitive moment for the diagnostics sector, where companies like Natera have aggressively expanded their testing portfolios and marketing reach. Investors in both firms are likely to scrutinize the ruling's practical implications for CareDx's ability to contest Natera's market claims and for any potential damages or injunctive relief still in play at lower court levels.
Continue reading at Yahoo Finance.
